Crinetics Pharmaceuticals Ownership | Who Owns Crinetics Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Crinetics Pharmaceuticals Ownership Summary


Crinetics Pharmaceuticals is owned by 42.57% institutional investors, 1.60% insiders, and 55.83% retail investors. Fmr is the largest institutional shareholder, holding 16.76% of CRNX shares. Vanguard Health Care Inv is the top mutual fund, with 3.31% of its assets in Crinetics Pharmaceuticals shares.

CRNX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCrinetics Pharmaceuticals42.57%1.60%55.83%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.80%11.85%52.35%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr15.76M16.76%$572.40M
Vanguard group9.14M9.70%$425.26M
Blackrock funding, inc. /de8.48M9.01%$307.95M
Farallon capital management8.34M8.86%$302.84M
Wellington management group llp8.16M8.67%$296.27M
Blackrock6.23M8.62%$279.06M
Driehaus capital management6.40M6.80%$232.30M
Price t rowe associates inc /md/5.36M5.69%$194.51M
Janus henderson group4.52M4.81%$164.23M
Ecor1 capital4.29M4.56%$155.74M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
New leaf venture partners141.00K13.64%$5.87M
Ecor1 capital4.29M6.61%$155.74M
Novo1.55M4.56%$56.30M
First light asset management1.09M3.55%$39.58M
Ghost tree capital240.00K3.37%$10.75M
Bellevue group3.28M2.84%$119.13M
Semanteon capital management, lp5.56K2.71%$202.01K
Prosight management, lp350.00K2.08%$12.71M
Siren1.90M1.92%$69.14M
Farallon capital management8.34M1.73%$302.84M

Top Buyers

HolderShares% AssetsChange
Bellevue group3.28M2.84%3.28M
T. rowe price investment management1.94M0.05%1.88M
Fmr15.76M0.03%1.47M
Farallon capital management8.34M1.73%1.41M
Suvretta capital management1.04M0.97%1.04M

Top Sellers

HolderShares% AssetsChange
Point72 asset management---2.34M
Paradigm biocapital advisors lp---2.21M
Vestal point capital, lp750.00K1.41%-750.00K
Lord, abbett---724.63K
Eventide asset management---609.01K

New Positions

HolderShares% AssetsChangeValue
Suvretta capital management1.04M0.97%1.04M$37.91M
Vanguard fiduciary trust708.47K0.01%708.47K$25.73M
Marshall wace, llp684.11K0.02%684.11K$24.85M
Braun stacey associates324.81K0.39%324.81K$11.80M
Foresite capital management vi212.01K1.67%212.01K$7.70M

Sold Out

HolderChange
Capital performance advisors llp-8.00
Cubist systematic strategies-13.00
Physician wealth advisors-15.00
Northwestern mutual wealth management-16.00
Bryn mawr trust-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026163-34.80%40,042,979-64.12%420.30%108-26.53%38-50.00%
Dec 31, 2025204-13.92%65,989,147-38.74%700.53%119-9.85%63-11.27%
Sep 30, 20252297.01%106,238,8544.14%1130.96%1270.79%719.23%
Jun 30, 2025219-2.67%104,541,9797.66%1111.02%1293.20%64-11.11%
Mar 31, 2025227-8.84%101,882,1252.21%1090.71%125-15.54%729.09%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv3.49M3.31%306.20K
Vanguard Total Stock Mkt Idx Inv3.36M3.19%11.62K
Fidelity OTC3.01M2.86%277.66K
Vanguard US Total Market Shares ETF2.40M2.58%2.45K
Vanguard Small Cap Index2.41M2.29%-8.48K
iShares Russell 2000 ETF2.30M2.18%19.36K
Polar Capital Biotech S Inc2.27M2.15%2.27M
US Small-Cap Growth II Equity Comp1.58M1.51%89.61K
T. Rowe Price New Horizons1.58M1.51%-
Vanguard Small Cap Growth Index Inv1.36M1.29%4.54K

Recent Insider Transactions


DateNameRoleActivityValue
Apr 08, 2026Knight Jeff E. Chief Dev. & Operating OfficerSell$3.42M
Mar 16, 2026Knight Jeff E. Chief Operating OfficerSell$220.80K
Mar 16, 2026Knight Jeff E. Chief Operating OfficerSell$149.61K
Mar 16, 2026Betz Stephen F. Chief Scientific OfficerSell$160.18K
Mar 16, 2026Betz Stephen F. Chief Scientific OfficerSell$236.43K

Insider Transactions Trends


DateBuySell
2026 Q2-1
2026 Q1-11
2025 Q4-4
2025 Q3-5
2025 Q2-1

CRNX Ownership FAQ


Who Owns Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals shareholders are primarily institutional investors at 42.57%, followed by 1.60% insiders and 55.83% retail investors. The average institutional ownership in Crinetics Pharmaceuticals's industry, Biotech Stocks , is 35.80%, which Crinetics Pharmaceuticals exceeds.

Who owns the most shares of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s largest shareholders are Fmr (15.76M shares, 16.76%), Vanguard group (9.14M shares, 9.70%), and Blackrock funding, inc. /de (8.48M shares, 9.01%). Together, they hold 35.47% of Crinetics Pharmaceuticals’s total shares outstanding.

Does Blackrock own Crinetics Pharmaceuticals?

Yes, BlackRock owns 8.62% of Crinetics Pharmaceuticals, totaling 6.23M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 279.06M$. In the last quarter, BlackRock increased its holdings by 794.27K shares, a 14.61% change.

Who is Crinetics Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

New leaf venture partners is Crinetics Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 13.64% of its assets in 141K Crinetics Pharmaceuticals shares, valued at 5.87M$.

Who is the top mutual fund holder of Crinetics Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Crinetics Pharmaceuticals shares, with 3.31% of its total shares outstanding invested in 3.49M Crinetics Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools